Cocrystal Pharma Inc.

1.05+0.0300+2.94%Vol 229.70K1Y Perf 8.28%
Sep 23rd, 2021 13:49 DELAYED
BID1.04 ASK1.05
Open1.02 Previous Close1.02
Pre-Market- After-Market-
 - -%  - -
Target Price
4.50 
Analyst Rating
— — 0.00
Potential %
332.69 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/-/- 
Value Ranking
★★★★+     58.48
Insiders Value % 3/6/12 mo.
100/-95/-95 
Growth Ranking
★★★★     60.45
Insiders Shares Cnt. % 3/6/12 mo.
100/-87/-87 
Income Ranking
 —    -
Price Range Ratio 52W %
10.74 
Earnings Rating
Buy
Market Cap102.34M 
Earnings Date
15th Nov 2021
Alpha0.01 Standard Deviation0.37
Beta0.72 

Today's Price Range

1.021.05

52W Range

0.76003.46

5 Year PE Ratio Range

-50.30-2.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-5.56%
1 Month
-4.67%
3 Months
-23.88%
6 Months
-27.14%
1 Year
8.28%
3 Years
-63.31%
5 Years
-93.27%
10 Years
-

TickerPriceChg.Chg.%
COCP1.050.03002.94
AAPL146.881.03000.71
GOOG2 841.7322.96000.81
MSFT300.071.49000.50
XOM57.081.87003.39
WFC48.070.99002.10
JNJ165.551.62000.99
FB346.783.57001.04
GE103.755.21005.29
JPM161.575.66003.63
Financial StrengthValueIndustryS&P 500US Markets
28.20
28.30
0.00
0.01
-1 530.70
Leverage Ratio 1.00
ProfitabilityValueIndustryS&P 500US Markets
-
-1 072.60
-1 035.80
-
-5.26
RevenueValueIndustryS&P 500US Markets
999.00K
0.01
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.04-0.040.00
Q01 2021-0.04-0.040.00
Q04 2020--0.01-
Q03 2020-0.05-0.050.00
Q02 2020-0.04-0.07-75.00
Q01 2020--0.05-
Q03 2019--0.06-
Q02 2019--0.05-
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.030.00-
12/2021 QR-0.040.00-
12/2021 FY-0.130.00-
12/2022 FY-0.150.00-
Next Report Date15th Nov 2021
Estimated EPS Next Report-0.03
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume229.70K
Shares Outstanding97.47M
Shares Float81.45M
Trades Count620
Dollar Volume2.21M
Avg. Volume8.01M
Avg. Weekly Volume664.86K
Avg. Monthly Volume1.22M
Avg. Quarterly Volume4.28M

Cocrystal Pharma Inc. (NASDAQ: COCP) stock closed at 1.02 per share at the end of the most recent trading day (a -2.86% change compared to the prior day closing price) with a volume of 932.19K shares and market capitalization of 102.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Cocrystal Pharma Inc. CEO is Gary L. Wilcox.

The one-year performance of Cocrystal Pharma Inc. stock is 8.28%, while year-to-date (YTD) performance is -25%. COCP stock has a five-year performance of -93.27%. Its 52-week range is between 0.76 and 3.46, which gives COCP stock a 52-week price range ratio of 10.74%

Cocrystal Pharma Inc. currently has a PE ratio of -7.50, a price-to-book (PB) ratio of 1.21, a price-to-sale (PS) ratio of 99.52, a price to cashflow ratio of 54.20, a PEG ratio of 2.32, a ROA of -16.48%, a ROC of -17.42% and a ROE of -17.31%. The company’s profit margin is -5.26%, its EBITDA margin is -1 035.80%, and its revenue ttm is $999.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Cocrystal Pharma Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.03 for the next earnings report. Cocrystal Pharma Inc.’s next earnings report date is 15th Nov 2021.

The consensus rating of Wall Street analysts for Cocrystal Pharma Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cocrystal Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cocrystal Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cocrystal Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.65, ATR14 : 0.05, CCI20 : -126.75, Chaikin Money Flow : -0.03, MACD : -0.02, Money Flow Index : 24.61, ROC : -10.53, RSI : 40.73, STOCH (14,3) : 10.10, STOCH RSI : 0.19, UO : 50.98, Williams %R : -89.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cocrystal Pharma Inc. in the last 12-months were: Raymond F. Schinazi (Sold 575 000 shares of value $1 696 250 ), Richard C. Pfenniger (Buy at a value of $41 120)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.

CEO: Gary L. Wilcox

Telephone: +1 786 459-1831

Address: 19805 North Creek Parkway, Bothell 98011, WA, US

Number of employees: 11

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

78%22%

Bearish Bullish

56%44%

Bearish Bullish

51%49%

News

Stocktwits